UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
X Quarterly report pursuant to Section 13 or 15(d) of the Securities
- ---- Exchange Act of 1934. For the quarterly period ended June 30, 1999.
Transition report pursuant to Section 13 or 15(d) of the Securities
- ---- Exchange Act of 1934. For the transition period from _____ to _____.
Commission File Number
0-27410
INCARA PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware 56-1924222
- ------------------------------- ---------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
P.O. Box 14287
3200 East Highway 54
Cape Fear Building, Suite 300
Research Triangle Park, NC 27709
- --------------------------------------- -----------------------------------
(Address of Principal Executive Office) (Zip Code)
Registrant's Telephone Number, Including Area Code 919-558-8688
---------------------------
INTERCARDIA, INC.
-----------------
(Former Name)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. YES [X] NO [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Class Outstanding as of August 10, 1999
- ----------------------------- ---------------------------------
Common Stock, par value $.001 3,982,957 Shares
<PAGE>
INCARA PHARMACEUTICALS CORPORATION
INDEX TO FORM 10-Q
PAGE
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets as of June 30, 1999 (unaudited)
and September 30, 1998................................................3
Consolidated Statements of Operations for the Three Months and Nine
Months ended June 30, 1999 and 1998 (unaudited).......................4
Consolidated Statements of Cash Flows for the Nine Months ended
June 30, 1999 and 1998 (unaudited)....................................5
Notes to Consolidated Financial Statements............................6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.........................10
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K............................17
SIGNATURE............................................................18
2
<PAGE>
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)
<TABLE>
<CAPTION>
June 30, September 30,
1999 1998
----------------- ------------------
<S> <C> <C>
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 5,548 $ 10,647
Marketable securities 2,545 9,314
Accounts receivable 27 1,096
Prepaids and other current assets 116 117
----------------- ------------------
Total current assets 8,236 21,174
Marketable securities --- 3,601
Property and equipment, net 2,672 2,976
Other assets 83 85
================= ==================
$ 10,991 $ 27,836
================= ==================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 795 $ 752
Accrued expenses 1,780 3,191
Current portion of capital lease obligations 492 565
Current portion of notes payable 216 194
Accounts payable to Interneuron 2,116 1,865
----------------- ------------------
Total current liabilities 5,399 6,567
Long-term portion of capital lease obligations 521 816
Long-term portion of notes payable 626 777
Stockholders' equity:
Common stock, $.001 par value per share, 40,000,000 shares
authorized, 7,341,605 and 7,289,153 shares issued and
outstanding at June 30, 1999 and September 30, 1998,
respectively 7 7
Additional paid-in capital 78,963 78,399
Deferred compensation (465) (1,086)
Accumulated deficit (74,060) (57,644)
----------------- ------------------
Total stockholders' equity 4,445 19,676
----------------- ------------------
$ 10,991 $ 27,836
================= ==================
</TABLE>
The accompanying notes are an integral part of these
consolidated financial statements.
3
<PAGE>
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
June 30, June 30,
-------------------------------- --------------------------------
1999 1998 1999 1998
-------------- --------------- -------------- ---------------
<S> <C> <C> <C> <C>
Revenue:
Contract and license fee revenue $ 188 $ 577 $ 588 $ 1,662
-------------- --------------- -------------- ---------------
Costs and expenses:
Research and development 3,654 4,760 15,074 10,896
Purchase of in-process research
and development --- 5,343 --- 5,343
General and administrative 777 782 2,266 2,938
-------------- --------------- -------------- ---------------
Total costs and expenses 4,431 10,885 17,340 19,177
-------------- --------------- -------------- ---------------
Loss from operations (4,243) (10,308) (16,752) (17,515)
Investment income, net 124 119 336 174
-------------- --------------- -------------- ---------------
Net loss $(4,119) $(10,189) $(16,416) $(17,341)
============== =============== ============== ===============
Net loss per common share:
Basic $ (0.56) $ (1.42) $ (2.24) $ (2.46)
============== =============== ============== ===============
Diluted $ (0.56) $ (1.42) $ (2.24) $ (2.46)
============== =============== ============== ===============
Weighted average common shares
outstanding 7,341 7,168 7,315 7,057
============== =============== ============== ===============
</TABLE>
The accompanying notes are an integral part of
these consolidated financial statements.
4
<PAGE>
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
<TABLE>
<CAPTION>
Nine Months Ended
June 30,
--------------------------------
1999 1998
-------------- ---------------
<S> <C> <C>
Cash flows from operating activities:
Net loss $(16,416) $(17,341)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 582 1,508
Noncash compensation 1,018 820
Purchase of in-process research and development --- 5,343
Change in assets and liabilities:
Accounts receivable 1,069 (195)
Prepaids and other assets 3 27
Accounts payable and accrued expenses (1,368) (9,926)
Deferred revenue --- (500)
-------------- ---------------
Net cash used in operating activities (15,112) (20,264)
-------------- ---------------
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities 11,414 20,479
Purchases of marketable securities (1,044) (12,288)
Purchases of property and equipment (278) (1,076)
-------------- ---------------
Net cash provided by investing activities 10,092 7,115
-------------- ---------------
Cash flows from financing activities:
Net proceeds from issuance of stock 167 176
Advances from Interneuron, net 251 6,272
Proceeds from sale/leaseback transactions --- 380
Principal payments on notes payable (129) (37)
Principal payments on capital lease obligations (368) (590)
-------------- ---------------
Net cash provided by (used in) financing activities (79) 6,201
-------------- ---------------
Net decrease in cash and cash equivalents (5,099) (6,948)
Cash and cash equivalents at beginning of period 10,647 18,185
============== ===============
Cash and cash equivalents at end of period $ 5,548 $11,237
============== ===============
</TABLE>
The accompanying notes are integral part of
these consolidated financial statements.
5
<PAGE>
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A. Basis of Presentation
On July 16, 1999, Intercardia, Inc. changed its name to Incara
Pharmaceuticals Corporation. The "Company" refers collectively to Incara
Pharmaceuticals Corporation ("Incara") and its majority-owned subsidiaries,
Aeolus Pharmaceuticals, Inc., a Delaware corporation ("Aeolus"), Renaissance
Cell Technologies, Inc., a Delaware corporation ("Renaissance") and CPEC, Inc.,
a Nevada corporation. As of June 30, 1999, Incara owned 65.8% of the outstanding
stock of Aeolus, 79.6% of the outstanding stock of Renaissance and 80.1% of the
outstanding stock of CPEC, Inc. Incara reduced its ownership of the successor to
CPEC, Inc. to 35.0% in a series of transactions on July 15, 1999. As of June 30,
1999, Interneuron Pharmaceuticals, Inc. ("Interneuron") owned 61.4% of the
outstanding capital stock of Incara and the 19.9% of the outstanding stock of
CPEC, Inc. not owned by Incara. On July 15, 1999, Interneuron's ownership of
Incara was reduced to 9.0% and its ownership of the successor to CPEC, Inc. was
increased to 65.0% (see Note C "Subsequent Events"). The Company focuses on the
development of therapeutics for the treatment of infectious diseases,
inflammatory bowel diseases, liver disorders and other conditions.
All significant intercompany activity has been eliminated in the
preparation of the consolidated financial statements. The consolidated financial
statements included herein have been prepared by the Company without audit,
pursuant to the rules and regulations of the Securities and Exchange Commission
(the "SEC"). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to such rules and
regulations. In the opinion of management, the accompanying unaudited
consolidated financial statements include all adjustments (consisting only of
normal recurring adjustments) necessary to present fairly the consolidated
financial position, results of operations and cash flows of the Company. The
consolidated balance sheet at September 30, 1998 was derived from the Company's
audited financial statements included in the Company's Annual Report on Form
10-K. The unaudited consolidated financial statements included herein should be
read in conjunction with the audited consolidated financial statements and the
notes thereto included in the Company's Annual Report on Form 10-K for the
fiscal year ended September 30, 1998 and in the Company's other SEC filings.
Results for the interim period are not necessarily indicative of the results for
any other interim period or for the full fiscal year.
B. Recent Accounting Pronouncements
The Company adopted the provisions of Statement of Financial Accounting
Standards ("SFAS") No. 130, "Reporting Comprehensive Income," effective October
1, 1998. The Company had no items of comprehensive income for the three months
or nine months ended June 30, 1999 or 1998.
6
<PAGE>
The Company will adopt SFAS No. 131, "Disclosures About Segments of an
Enterprise and Related Information," for the fiscal year ending September 30,
1999. SFAS No. 131 specifies revised guidelines for determining an entity's
operating segments and the type and level of financial information to be
disclosed. Management believes its current disclosures will not be materially
affected by the adoption of SFAS No. 131.
C. Subsequent Events
MERCK MILESTONE
On August 9, 1999, Incara announced that it received notification from
Merck & Co., Inc. ("Merck") that Incara had been awarded the initial milestone
in the 1997 collaboration targeting the discovery and development of a class of
vancomycin analogues (the "Merck Collaboration"). The milestone, which requires
that compounds synthesized in the collaboration demonstrate specified IN VITRO
and IN VIVO activity in both resistant and sensitive bacterial strains,
triggered a $1,500,000 payment from Merck. Incara's collaboration with Merck is
based on research sponsored by Incara in the laboratory of Professor Daniel
Kahne, Ph.D., of the Chemistry Department of Princeton University. Pursuant to
its license agreement with Princeton University related to this class of
vancomycin analogues, Incara paid Princeton University $510,000 of the
$1,500,000 milestone payment.
TERMINATION OF BEST AND BEAT
On July 29, 1999, Incara was notified that the National Institutes of
Health ("NIH") and the Department of Veterans Affairs ("VA") had terminated the
double-blind, placebo-controlled, Phase 3 study of BEXTRA(R) (bucindolol HCl)
known as BEST (Beta-blocker Evaluation of Survival Trial) earlier than
scheduled, based on an interim analysis by the Data and Safety Monitoring Board
("DSMB") that treatment with bucindolol did not demonstrate a statistically
significant improvement in survival in the patient population as a whole. BEST
was designed to evaluate BEXTRA's use in treating patients with moderate to
severe congestive heart failure. Incara has not received the data from BEST or
the DSMB's interim analysis. Pending receipt and analysis of the BEST data, U.S.
bucindolol development is on hold.
On August 3, 1999, BASF Pharma/Knoll AG ("Knoll") terminated the 1996
development agreement among Knoll, Incara and CPEC (the "Knoll Collaboration"),
following the decision by the NIH and VA to terminate BEST. Knoll and the
Company also terminated the Phase 3 clinical study of bucindolol being conducted
in Europe, which was known as BEAT (Bucindolol Evaluation after Acute myocardial
infarction Trial).
RESTRUCTURING OF RELATIONSHIP WITH INTERNEURON AND CPEC
On July 15, 1999, Incara restructured its corporate relationship with
Interneuron and CPEC, Inc., to reduce Interneuron's 61.4% ownership of Incara to
9.0% and to reduce Incara's ownership of CPEC, Inc. from 80.1% to 35.0% (the
"Restructuring"). CPEC holds the rights to BEXTRA, including the exclusive,
worldwide license from Bristol-Myers Squibb Company to
7
<PAGE>
develop bucindolol for congestive heart failure and left ventricular
dysfunction. As a preliminary step in the Restructuring, Incara acquired
Interneuron's 19.9% interest in CPEC, Inc., which was then merged into CPEC LLC,
a Delaware limited liability company ("CPEC"). Incara redeemed 4,229,381 of the
4,511,084 shares of Incara Common Stock owned by Interneuron, in exchange for a
65% ownership of CPEC and cancellation of certain debt owed to Interneuron by
Incara and CPEC, Inc.
Before the Restructuring, Incara had funded approximately 80.1% of the
worldwide expenses related to bucindolol and Interneuron funded approximately
19.9%, which was in proportion to their respective ownership interests in CPEC,
Inc. With the Restructuring, Incara and Interneuron are responsible for funding
35% and 65%, respectively, of CPEC's expenses related to the development of
BEXTRA in the United States and Japan (the "CPEC Territory"). Incara is
responsible for bucindolol expenses in the countries outside the CPEC Territory.
Interneuron and Incara each pre-paid its share of the estimated
expenditures for BEXTRA development through December 31, 1999. Incara's share of
this pre-payment was $824,000. Activities related to the U.S. development of
BEXTRA have been terminated or suspended indefinitely, pending receipt and
review of the data from the recently terminated BEST study, which is not
expected for at least several months. Some costs, such as completion of clinical
monitoring of BEST and storage of clinical supplies, will continue to be
incurred, although Incara and Interneuron are taking steps where possible to
minimize those costs.
The rights to develop and market bucindolol in all countries other than
the United States and Japan (such other countries being referred to as the
"Knoll Territory") were licensed to Knoll under the Knoll Collaboration. As part
of the Restructuring, Incara received an exclusive license of CPEC's rights in
the Knoll Territory. However, Knoll and Incara subsequently terminated the Knoll
Collaboration and BEAT. Some costs, such as BEAT termination costs, will
continue to be incurred, although Incara and Knoll are taking steps to minimize
those costs.
The Company does not believe that any restatement of its historical
financial statements is required as a result of the Restructuring. For
subsequent periods, however, Incara will no longer consolidate CPEC, Inc. in its
consolidated financial statements. Instead, Incara will account for its 35%
interest in CPEC LLC using the equity method. As part of the Restructuring,
Interneuron cancelled approximately $2.2 million of debt owed to it by CPEC,
Inc. This cancellation of debt will be treated as a contribution to capital by
Interneuron to Incara.
Incara will recognize a taxable gain on the sale of 65% of CPEC to
Interneuron. Management of Incara believes that it has current operating losses,
net operating loss carryforwards and tax credit carryforwards sufficient to
offset this taxable gain.
The 1995 Intercompany Services Agreement between Interneuron and Incara
was terminated upon the Restructuring. Glenn L. Cooper, M.D., President and
Chief Executive Officer of Interneuron, resigned as Chairman of the Board and a
director of Incara, upon completion of the Restructuring.
8
<PAGE>
Arrangements related to Incara's May 1998 purchase of Transcell
Technologies, Inc. ("Transcell", now operating as Incara Research Laboratories)
from Interneuron (the "Transcell Merger") continue after the Restructuring,
including Incara's obligations to pay a 1.5% royalty to Interneuron on sales of
products, if any, resulting from the Merck Collaboration. However, in lieu of
the second stock issuance installment payment due to Interneuron in connection
with the Transcell Merger, Interneuron retained 281,703 shares of Incara Common
Stock as part of the Restructuring.
On August 9, 1999, Incara issued 867,583 shares of Incara Common Stock,
valued at approximately $1.38 per share, to the other former Transcell
stockholders as payment for their second stock issuance installment of the
Transcell Merger in the principal amount of $1,202,000. The third and final
stock issuance installment of approximately $3,000,000 to the former Transcell
stockholders, including Interneuron, is due in February 2000 and will be paid in
shares of Incara Common Stock, calculated based on the per share price at that
time. The impact of the issuance of these additional shares has not been
reflected in Incara's Common Stock outstanding or its net loss per share
calculations, but was included in the determination of the value of the purchase
price of Transcell in the third quarter of fiscal 1998.
9
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Introduction
The "Company" refers collectively to Incara Pharmaceuticals Corporation
("Incara") and its majority-owned subsidiaries, Aeolus Pharmaceuticals, Inc., a
Delaware corporation ("Aeolus"), Renaissance Cell Technologies, Inc., a Delaware
corporation ("Renaissance") and CPEC, Inc., a Nevada corporation.
This Report contains, in addition to historical information, statements
by the Company with respect to expectations about its business and future
results, which are "forward-looking" statements under the Private Securities
Litigation Reform Act of 1995. These statements and other statements made
elsewhere by the Company or its representatives, which are identified or
qualified by words such as "likely," "will," "suggests," "expects," "might,"
"believe," "could," "should," "would," "anticipates" or "plans," or similar
expressions, are based on a number of assumptions that are subject to risks and
uncertainties. Actual results could differ materially from those currently
anticipated or suggested due to a number of factors, including those set forth
herein, those set forth in the Company's Annual Report on Form 10-K and in the
Company's other SEC filings, and including risks relating to the need for
additional funds, dependence on collaborative partners, competition, the early
stage of products under development, and uncertainties relating to clinical
trials and regulatory reviews. All forward-looking statements are based on
information available as of the date hereof, and the Company does not assume any
obligation to update such forward-looking statements.
Subsequent Events
MERCK MILESTONE
On August 9, 1999, Incara announced that it received notification from
Merck & Co., Inc. ("Merck") that Incara had been awarded the initial milestone
in the 1997 collaboration targeting the discovery and development of a class of
vancomycin analogues (the "Merck Collaboration"). The milestone, which requires
that compounds synthesized in the collaboration demonstrate specified IN VITRO
and IN VIVO activity in both resistant and sensitive bacterial strains,
triggered a $1,500,000 payment from Merck. Incara's collaboration with Merck is
based on research sponsored by Incara in the laboratory of Professor Daniel
Kahne, Ph.D., of the Chemistry Department of Princeton University. Pursuant to
its license agreement with Princeton University related to this class of
vancomycin analogues, Incara paid Princeton University $510,000 of the
$1,500,000 milestone payment.
TERMINATION OF BEST AND BEAT
On July 29, 1999, Incara was notified that the National Institutes of
Health ("NIH") and the Department of Veterans Affairs ("VA") had terminated the
double-blind, placebo-controlled, Phase 3 study of BEXTRA(R) (bucindolol HCl)
known as BEST (Beta-blocker Evaluation of
10
<PAGE>
Survival Trial) earlier than scheduled, based on an interim analysis by the Data
and Safety Monitoring Board ("DSMB") that treatment with bucindolol did not
demonstrate a statistically significant improvement in survival in the patient
population as a whole. BEST was designed to evaluate BEXTRA's use in treating
patients with moderate to severe congestive heart failure. Incara has not
received the data from BEST or the DSMB's interim analysis. Pending receipt and
analysis of the BEST data, U.S. bucindolol development is on hold.
On August 3, 1999, BASF Pharma/Knoll AG ("Knoll") terminated the 1996
development agreement among Knoll, Incara and CPEC (the "Knoll Collaboration"),
following the decision by the NIH and VA to terminate BEST. Knoll and the
Company also terminated the Phase 3 clinical study of bucindolol being conducted
in Europe, which was known as BEAT (Bucindolol Evaluation after Acute myocardial
infarction Trial).
RESTRUCTURING OF RELATIONSHIPS WITH INTERNEURON AND CPEC
On July 15, 1999, Incara restructured its corporate relationship with
Interneuron and CPEC, Inc., to reduce Interneuron's 61.4% ownership of Incara to
9.0% and to reduce Incara's ownership of CPEC, Inc. from 80.1% to 35.0% (the
"Restructuring"). CPEC holds the rights to BEXTRA, including the exclusive,
worldwide license from Bristol-Myers Squibb Company to develop bucindolol for
congestive heart failure and left ventricular dysfunction. As a preliminary step
in the Restructuring, Incara acquired Interneuron's 19.9% interest in CPEC,
Inc., which was then merged into CPEC LLC, a Delaware limited liability company
("CPEC"). Incara redeemed 4,229,381 of the 4,511,084 shares of Incara Common
Stock owned by Interneuron, in exchange for a 65% ownership of CPEC and
cancellation of certain debt owed to Interneuron by Incara and CPEC, Inc.
Before the Restructuring, Incara had funded approximately 80.1% of the
worldwide expenses related to bucindolol and Interneuron funded approximately
19.9%, which was in proportion to their respective ownership interests in CPEC,
Inc. With the Restructuring, Incara and Interneuron are responsible for funding
35% and 65%, respectively, of CPEC's expenses related to the development of
BEXTRA in the United States and Japan (the "CPEC Territory"). Incara is
responsible for bucindolol expenses in the countries outside the CPEC Territory.
Interneuron and Incara each pre-paid its share of the estimated
expenditures for BEXTRA development through December 31, 1999. Incara's share of
this pre-payment was $824,000. Activities related to the U.S. development of
BEXTRA have been terminated or suspended indefinitely, pending receipt and
review of the data from the recently terminated BEST study, which is not
expected for at least several months. Some costs, such as completion of clinical
monitoring of BEST and storage of clinical supplies, will continue to be
incurred, although Incara and Interneuron are taking steps where possible to
minimize those costs.
Decisions on future development of BEXTRA, if any, in the CPEC
Territory will be made under the terms of an Amended and Restated Limited
Liability Company Agreement between Incara and Interneuron (the "LLC
Agreement"), which governs the management, funding and income-sharing activities
related to BEXTRA in the CPEC Territory. The Board of Directors of CPEC consists
of three directors designated by Interneuron and two directors
11
<PAGE>
designated by Incara. The LLC Agreement contains provisions for dispute
resolution and arbitration and identifies the transactions involving CPEC that
require Incara approval. The LLC Agreement also provides for adjustments to
ownership percentages if a party defaults on its funding obligations, subject to
a maximum adjustment of 10%.
The rights to develop and market bucindolol in all countries other than
the United States and Japan (such other countries being referred to as the
"Knoll Territory") were licensed to Knoll under the Knoll Collaboration. As part
of the Restructuring, Incara received an exclusive license of CPEC's rights in
the Knoll Territory. However, Knoll and Incara subsequently terminated the Knoll
Collaboration and BEAT. Some costs, such as BEAT termination costs, will
continue to be incurred, although Incara and Knoll are taking steps to minimize
those costs.
Results of Operations
The Company incurred net losses of $4,119,000 and $16,416,000 for the
three and nine months ended June 30, 1999, respectively, versus net losses of
$10,189,000 and $17,341,000 for the three and nine months ended June 30, 1998,
respectively.
The Company's net loss decreased from $6,121,000 and $6,175,000 for the
first and second quarters of fiscal 1999, respectively, to $4,119,000 for the
third quarter of fiscal 1999. The decrease in the net loss was primarily the
result of decreases in research and development expenses incurred for clinical
trials of BEXTRA and decreases in costs as a result of the March 1999 reduction
of personnel at Incara Research Laboratories ("IRL").
Contract and license fee revenue decreased by $389,000 (67%) to
$188,000 for the three months ended June 30, 1999 from $577,000 for the three
months ended June 30, 1998. Contract and license fee revenue decreased by
$1,074,000 (65%) to $588,000 for the nine months ended June 30, 1999 from
$1,662,000 for the nine months ended June 30, 1998. These decreases were due
primarily to the termination in September 1998 of a collaboration between the
Company and Astra Merck Inc. ("Astra Merck") for the U.S. development and
commercialization of bucindolol (the "Astra Merck Collaboration"). Contract and
license fee revenue of $188,000 and $588,000 for the three months and nine
months ended June 30, 1999, respectively, consisted primarily of contract
revenue payments from Merck pursuant to the Merck Collaboration. Contract and
license fee revenue of $577,000 and $1,662,000 for the three months and nine
months ended June 30, 1998, respectively, consisted primarily of contract
revenue payments received from both the Merck Collaboration and the Astra Merck
Collaboration.
Research and development ("R&D") expenses decreased by $1,106,000 (23%)
to $3,654,000 for the three months ended June 30, 1999 from $4,760,000 for the
three months ended June 30, 1998. R&D expenses increased by $4,178,000 (38%) to
$15,074,000 for the nine months ended June 30, 1999 from $10,896,000 for the
nine months ended June 30, 1998.
Bucindolol and general R&D expenses increased by $182,000 (15%) to
$1,357,000 for the three months ended June 30, 1999 from $1,175,000 for the
three months ended June 30, 1998. Bucindolol and general R&D expenses increased
by $3,779,000 (134%) to $6,589,000 for the nine months ended June 30, 1999 from
$2,810,000 for the nine months ended June 30, 1998.
12
<PAGE>
These increases were primarily due to increases in the Company's share of
bucindolol clinical trial costs associated with BEAT in Europe and BEST in the
United States. In June 1998, Knoll, the Company's international partner for
BEXTRA, initiated BEAT in Denmark and the United Kingdom. The Company's share of
costs for BEST, which began in June 1995, for the three months and nine months
ended June 30, 1999 increased significantly over the prior fiscal year due to
the termination of the Astra Merck Collaboration in September 1998. Astra Merck
had assumed approximately $1,500,000 and $4,800,000 of BEST and U.S. bucindolol
development costs for the three months and nine months ended June 30, 1998,
respectively.
IRL R&D expenses decreased by $1,238,000 (43%) to $1,660,000 for the
three months ended June 30, 1999 from $2,898,000 for the three months ended June
30, 1998. This decrease results from the Company's March 1999 reduction of its
personnel at IRL from 32 employees to 14 employees as part of a re-focusing of
IRL's research programs. IRL R&D expenses increased by $343,000 (6%) to
$6,275,000 for the nine months ended June 30, 1999 from $5,932,000 for the nine
months ended June 30, 1998. This increase includes a charge of $180,000 for
severance related costs and increases in research support and license fees paid
to Princeton University, patent fees and noncash compensation to consultants.
Aeolus R&D expenses decreased by $121,000 (24%) to $389,000 for the
three months ended June 30, 1999 from $510,000 for the three months ended June
30, 1998. This decrease was primarily due to decreases in sponsored research
expenses. Aeolus R&D expenses decreased by $27,000 (2%) to $1,634,000 for the
nine months ended June 30, 1999 from $1,661,000 for the nine months ended June
30, 1998.
Renaissance R&D expenses for its liver stem cell program increased by
$71,000 (40%) to $248,000 for the three months ended June 30, 1999 from $177,000
for the three months ended June 30, 1998. Renaissance R&D expenses increased by
$83,000 (17%) to $576,000 for the nine months ended June 30, 1999 from $493,000
for the nine months ended June 30, 1998. These increases were primarily due to
the preparation and filing of new patent applications related to Renaissance's
research program.
During the three months and nine months ended June 30, 1998, the
Company incurred charges to operations of $5,343,000 for the non-Interneuron
portion of Transcell in-process research and development acquired in the
Transcell Merger.
General and administrative ("G&A") expenses decreased by $5,000 (1%) to
$777,000 for the three months ended June 30, 1999 from $782,000 for the three
months ended June 30, 1998. G&A expenses decreased by $672,000 (23%) to
$2,266,000 for the nine months ended June 30, 1999 from $2,938,000 for the nine
months ended June 30, 1998. This decrease was primarily due to the elimination
of certain IRL personnel and administrative functions after the Transcell
Merger.
Liquidity and Capital Resources
As of June 30, 1999, the Company had cash, cash equivalents and
marketable securities of $8,093,000, which was $15,469,000 less than the balance
at September 30, 1998. This
13
<PAGE>
decrease was primarily due to the funding of the Company's operations for the
nine month period ended June 30, 1999, which included increased expenses related
to BEXTRA following termination of the collaboration with Astra Merck in
September 1998 and the expenses associated with the operation of IRL, which was
acquired in May 1998. The Company believes its cash and cash resources,
including the net milestone payment of $990,000 received from Merck after the
end of the quarter, are sufficient to fund planned expenditures through December
31, 1999. The Company will require additional financing to fund operations
beyond December 31, 1999. Progress under the collaboration with Merck is not
under the control of the Company, and there can be no assurance of any further
milestone payments. In addition, the funding from Merck for the research
collaboration with Merck expired in accordance with its terms on June 30, 1999.
The Company does not expect that the termination of BEST and BEAT will
significantly reduce its expenses related to those programs during the fourth
quarter of fiscal 1999, because reductions from terminated activities will be
offset at least in part by costs associated with termination of BEXTRA
development activities and costs to maintain certain contracts pending receipt
and review of the BEST data. The Company's cash requirements for subsequent
periods will depend on numerous factors, particularly the progress of its
research and development programs. Significant additional funds will be required
if the Company proceeds with a clinical program evaluating use of OP2000, a
low-weight molecular heparin, in the treatment of inflammatory bowel disease,
and if the development activities of Renaissance require additional laboratory
facilities for the preparation of hepatic stem cells as a potential therapy for
liver disorders.
Management is evaluating the allocation of available resources for each
program to determine whether increases or reductions of operating expenses are
appropriate. If the Company is unable to obtain adequate funds for these
programs, it will be necessary to delay or terminate some or all of these
activities.
During the remainder of 1999, the Company intends to seek additional
capital through collaborative partnering arrangements, debt financing or equity
financing. However, the Company has no agreements or commitments to obtain
additional funds. Adequate funds might not be available at all or on terms
acceptable or favorable to the Company. It is currently difficult for
biotechnology companies to raise funds in the equity markets. Any additional
equity financing, if available, would result in substantial dilution to Incara's
stockholders. The Company has not established banking arrangements through which
it can obtain additional debt financing. If the Company is successful in
obtaining collaborations for any of its R&D programs, it expects to relinquish
rights to technologies, product candidates or markets which it may otherwise
develop itself. If the Company is unable to enter into additional collaborations
or raise additional capital to support its current level of operations, the
Company would be required to scale back, delay or discontinue one or more of its
research and development programs, or obtain funds on terms that are not
favorable to the Company or its existing stockholders, which could have a
material adverse affect on the Company's business. Reduction or discontinuation
of research and development programs could result in additional charges, which
would be reflected in the period of such reduction or discontinuation.
14
<PAGE>
In lieu of the second stock issuance installment payment due to
Interneuron in connection with the Transcell Merger, Interneuron retained
281,703 shares of Incara Common Stock as part of the Restructuring. On August 9,
1999, Incara issued 867,583 shares of Incara Common Stock, valued at
approximately $1.38 per share, to the other former Transcell stockholders as
payment for their second stock issuance installment of the Transcell Merger in
the principal amount of $1,202,000. The third and final stock issuance
installment of approximately $3,000,000 to the former Transcell stockholders,
including Interneuron, is due in February 2000 and will be paid in shares of
Incara Common Stock, calculated based on the per share price at such time. The
impact of the issuance of these additional shares has not been reflected in
Incara's Common Stock outstanding or its net loss per share calculations, but
was included in the determination of the value of the purchase price of
Transcell in the third quarter of fiscal 1998.
Incara will recognize a taxable gain on the sale of 65% of CPEC to
Interneuron. Management of Incara believes that it has current operating losses,
net operating loss carryforwards and tax credit carryforwards sufficient to
offset this taxable gain.
Year 2000
The Company recognizes the need to ensure that "Year 2000" hardware and
software issues will not adversely impact its operations. In 1998, the Company
initiated a program, and subsequently established a Year 2000 committee, to
assess the expected impact of the Year 2000 date recognition problem on its
existing internal systems, those which it intends to implement and the systems
of its key business vendors. The purpose of this program is to attempt to ensure
that this problem does not have a material adverse effect on the Company's
business operations or its financial condition. Key financial, information and
operational systems, including equipment with embedded microprocessors, were
inventoried and assessed, and detailed plans have been finalized to ready the
Company's internal operating systems. Currently the members of the Year 2000
committee are in the process of upgrading or replacing systems that were
determined to be non-compliant. As of June 30, 1999, the Company believes its
Year 2000 compliance programs were approximately 80% complete. The Company's
goal is to continue upgrading its personal computer hardware and software to
become fully Year 2000 compliant by the end of calendar 1999.
In addition, the Company is in the process of assessing key business
vendors' Year 2000 compliance to minimize the likelihood that non-compliance of
any vendor would significantly impact the Company's operations. Informational
requests have been distributed to all key business vendors in which they are
being requested to provide assurances regarding their Year 2000 compliance. As
replies are received, they are evaluated and further inquiries and discussions
are conducted as necessary. Risk assessment, readiness evaluation and action and
contingency plans related to these vendors are expected to be completed by
October 1999. Due to the Company's evolving internal systems and reliance on
third parties, the Company anticipates periodic re-evaluation and maintenance
regarding its internal systems and business vendors throughout 1999.
Due to the Company's relatively short operating history and evolving
internal systems, the modification or replacement of internal systems has not
been, nor is it expected to be, a
15
<PAGE>
material expenditure for the Company. Total expenditures to date for Year 2000
compliance have been less than $25,000 and additional expenditures are expected
to be less than $50,000. Expenditures required to make the Company Year 2000
compliant have been and will continue to be expensed as incurred. The Company
does not believe it has a risk of loss of significant revenues due to the Year
2000, because none of its potential pharmaceutical products will be producing
revenues in that time frame.
16
<PAGE>
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
11.1 Statement re computation of net loss per share
27 Financial Data Schedule, which is submitted electronically
to the Securities and Exchange Commission for information
only and not filed.
(b) No reports on Form 8-K were filed by the Company during the three
months ended June 30, 1999.
17
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION
Date: August 12, 1999 By: /s/ Richard W. Reichow
---------------------------------------------
Richard W. Reichow, Executive Vice President,
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
18
EXHIBIT 11.1
INCARA PHARMACEUTICALS CORPORATION
STATEMENT RE COMPUTATION OF NET LOSS PER SHARE
(In thousands, except per share data)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
June 30, June 30,
--------- ---------- ---------- ----------
1999 1998 1999 1998
--------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
Net loss per Unaudited Consolidated
Statements of Operations $ (4,119) $ (10,189) $ (16,416) $ (17,341)
========= ========== ========== ==========
Weighted average of common shares
and common share equivalents outstanding
- basic and diluted 7,341 7,168 7,315 7,057
========= ========== ========== ==========
Net loss per common share:
- basic $ (0.56) $ (1.42) $ (2.24) $ (2.46)
========= ========== ========== ==========
- diluted $ (0.56) $ (1.42) $ (2.24) $ (2.46)
========= ========== ========== ==========
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND THE CONSOLIDATED STATEMENT OF OPERATIONS FILED AS
PART OF THE QUARTERLY REPORT ON FORM 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH QUARTERLY REPORT ON FORM 10-Q.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> SEP-30-1999
<PERIOD-START> OCT-01-1998
<PERIOD-END> JUN-30-1999
<CASH> 5,548
<SECURITIES> 2,545
<RECEIVABLES> 27
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 8,236
<PP&E> 2,672
<DEPRECIATION> 0
<TOTAL-ASSETS> 10,991
<CURRENT-LIABILITIES> 5,399
<BONDS> 1,147
0
0
<COMMON> 7
<OTHER-SE> 4,438
<TOTAL-LIABILITY-AND-EQUITY> 10,991
<SALES> 0
<TOTAL-REVENUES> 588
<CGS> 0
<TOTAL-COSTS> 17,340
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (16,416)
<INCOME-TAX> 0
<INCOME-CONTINUING> (16,416)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (16,416)
<EPS-BASIC> (2.24)<F1>
<EPS-DILUTED> (2.24)
<FN>
<F1>EPS BASIC
</FN>
</TABLE>
